2nd_Computerized Asthma Specific Quality of Life(cAQOL)
- Conditions
- Persistent Asthma Patient
- Registration Number
- NCT01227083
- Lead Sponsor
- Ajou University School of Medicine
- Brief Summary
Comparison of the responsiveness of two different asthma-specific QOL measures (AQLQ and cAQOL) in Korean patients with persistent asthma
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 150
-
Patient aged 20-70 years
-
Patient diagnosed with asthma over six months ago
-
Asthma diagnosis
- Airway reversibility, FEV1 ≥ 12% and 200mL or
- Airway hyper-responsiveness, PC20 < 16 mg/mL or
- More than two weeks, more than 2 times a day in excess of 20% PEFR diurnal variability patient
-
FEV1 55-100% of predicted value patient
-
Inhaled corticosteroids alone or inhaled corticosteroids and beta agonists used patient
-
Currently, at least if you have one or more asthma symptoms, asthma control test (ACT • Asthma Control Test) score of less than 19 characters
-
Patients who sufficiently listen to the purpose and content of this trial and the properties of investigational products and voluntarily agree with the participation to sign a written consent approved by IRB of Ajou University Medical Center before the participation in this trial
- Current smoking or smoking in the past 15packyears
- Patients who show a symptom of an acute disease within 14 days before the beginning of this trial (administration of trial medication)
- Recent changes in asthma treatment for 28days
- Chronic diseases that affect the quality of life
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Two asthma quality of life measurement tool 24 weeks treatment Two asthma quality of life measurement tool (cAQOL, AQLQ) and the correlation between ACT
- Secondary Outcome Measures
Name Time Method Association of asthma control therapy and a questionnaire 24 weeks treatment -The proportion of subjects with achieving well controlled asthma within ACT \& cAQOL-guided management strategy with ICS or ICS/LABA based on GINA 2006 guidelines during 24 weeks.
asthma patient genotypes Screening Sub-group of ADRB2 and NK2R genotypes
Correlation between cAQOL/AQLQ treatment screening, week1,week12,week24 -Correlation between cAQOL/AQLQ and other clinical parameters including FEV1, and asthma exacerbation.
Trial Locations
- Locations (1)
Ajou University Medical Center
🇰🇷Suwon, Korea, Republic of